| SUPERNUS PHARMAC.DL -,001 |
| USA |
| Gesundheit |
| US8684591089 / A1JX3U |
| S49 (Frankfurt) / SUPN (NASDAQ) |
| FRA:S49, ETR:S49, S49:GR, NASDAQ:SUPN |
| - |
| https://www.supernus.com/ |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. Its primary function is to innovate therapeutic solutions that address..
>Volltext.. |
| 2492.21 Mio. EUR |
| 2266.95 Mio. EUR |
| 615.69 Mio. EUR |
| 41.77 Mio. EUR |
| -33.01 Mio. EUR |
| -0.58 EUR |
| 35.09 Mio. EUR |
| 110 Mio. EUR |
| 40.53 Mio. EUR |
| 0.91 |
| -4.25% |
| -146% |
| - |
| - |
| - |
| SUPERNUS |
| 08.04.26 |
|